About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Nebulized Ketamine for Severe Asthma Attacks in Children

NCT07728851·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Zahra Ali Al Lawati
CONTACT
+96892347374 zlawati@squ.edu.om

Lead

Sultan Qaboos University

Age

1–13

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Children aged 1 to 13 years.
Diagnosis of severe asthma exacerbation (PRAM score 8-12)
Prior treatment with standard first-line management (beta-2 agonist, corticosteroid, magnesium sulfate)

You may not be if

Known allergy or adverse reaction to ketamine
Significant hemodynamic instability
Systemic hypertension \>95th percentile for age
Cardiac arrhythmias
Congestive heart failure
Obstructive sleep apnea with AHI \>5

The record

StatusNot yet recruiting

PhasePhase 2

Taking part60

StartedJan 2027

UpdatedJul 27, 2026

Conditions

Asthma Acute Exacerbation of Allergic Asthma

Where1

Sultan Qaboos University Hospital
Muscat, Oman

Clareo Health | Nebulized Ketamine for Severe Asthma Attacks in Children